Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 1.00 |
| ▸ | DPP8 | Q6V1X1 | 15/20 | 1.00 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.71 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.71 |
| ▸ | FAP | Q12884 | 1/20 | 0.62 |
| ▸ | PREP | P48147 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14392573 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL3554784 | 1.00 | DPP4 (1.00) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL4412142 | 0.88 | DPP4 (0.78) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL4419185 | 0.84 | DPP4 (0.73) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL6453066 | 0.83 | DPP4 (1.00) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL14392585 | 0.83 | DPP4 (0.78) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL13444773 | 0.83 | DPP4 (0.84) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL13463796 | 0.83 | DPP4 (0.84) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL14392722 | 0.82 | DPP4 (1.00) | DPP4DPP8DPP7DPP9FAP | |
| SCHEMBL8275517 | 0.81 | DPP4 (0.71) | DPP4DPP8DPP7DPP9FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687504-B2 | 1-[3-[2-[2-cyano-(S)-pyrrolidin-1-yl]-2-oxo-ethylamino]-1-oxo-propyl]-4-[bis-(4-fluorophenyl)methyl]piperazine; inhibiting dipeptidyl peptidase IV or for treating Type II diabetes | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-03-30 | — | — | US | claimed |
| EP-1729774-A4 | PYRROLIDINE COMPOUNDS | NAT HEALTH RESEARCH INSTITUTES (TW) | 2009-05-06 | — | — | EP | claimed |
| EP-1729774-A1 | PYRROLIDINE COMPOUNDS | National Health Research Institutes (TW) | 2006-12-13 | — | — | EP | claimed |
| US-20050222222-A1 | Pyrrolidine compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2005-10-06 | — | — | US | claimed |
| WO-2005087235-A1 | PYRROLIDINE COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (CN) | 2005-09-22 | — | — | WO | claimed |
| US-7687504-B2 | 1-[3-[2-[2-cyano-(S)-pyrrolidin-1-yl]-2-oxo-ethylamino]-1-oxo-propyl]-4-[bis-(4-fluorophenyl)methyl]piperazine; inhibiting dipeptidyl peptidase IV or for treating Type II diabetes | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-03-30 | — | — | US | disclosed |
| US-7687504-B2 | 1-[3-[2-[2-cyano-(S)-pyrrolidin-1-yl]-2-oxo-ethylamino]-1-oxo-propyl]-4-[bis-(4-fluorophenyl)methyl]piperazine; inhibiting dipeptidyl peptidase IV or for treating Type II diabetes | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2010-03-30 | — | — | US | disclosed |
| EP-1729774-A4 | PYRROLIDINE COMPOUNDS | NAT HEALTH RESEARCH INSTITUTES (TW) | 2009-05-06 | — | — | EP | disclosed |
| EP-1729774-A1 | PYRROLIDINE COMPOUNDS | National Health Research Institutes (TW) | 2006-12-13 | — | — | EP | disclosed |
| US-20050222222-A1 | Pyrrolidine compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2005-10-06 | — | — | US | disclosed |
| WO-2005087235-A1 | PYRROLIDINE COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (CN) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222222-A1 | Pyrrolidine compounds | DPP4, DPP9, DPP7 | DPP4 1/4885DPP8 4/4885DPP7 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.